Hunan Cancer Hospital

Hunan Cancer Hospital logo
🇨🇳China
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.hnca.org.cn
Clinical Trials
Related News

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Recruiting
Conditions
HR+ Breast Cancer
First Posted Date
2024-12-16
Last Posted Date
2024-12-16
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
80
Registration Number
NCT06734533
Locations
🇨🇳

Hunan Provincial Tumor Hospital, Changsha, Hunan, China

18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors

Recruiting
Conditions
Cancer
FAP
First Posted Date
2024-08-16
Last Posted Date
2024-08-16
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
500
Registration Number
NCT06557590
Locations
🇨🇳

Hunan Cancer hospital, Changsha, Hunan, China

Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer

Recruiting
Conditions
Gastric Cancer
First Posted Date
2024-08-07
Last Posted Date
2024-08-07
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT06543108
Locations
🇨🇳

Hunan Cancer hospital, Changsha, Hunan, China

Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer

First Posted Date
2024-07-03
Last Posted Date
2024-08-26
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
18
Registration Number
NCT06486545

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Phase 2
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Cadonilimab
Drug: Lenvatinib
First Posted Date
2024-05-09
Last Posted Date
2024-05-09
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT06406634
Locations
🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

Phase 2
Recruiting
Conditions
Triple Negative Breast Neoplasms
Interventions
Drug: UTD1
First Posted Date
2024-04-26
Last Posted Date
2024-04-26
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
53
Registration Number
NCT06385990
Locations
🇨🇳

Quchang Ouyang, Changsha, Hunan, China

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Phase 2
Not yet recruiting
Conditions
Melanoma
Interventions
Drug: Cadonilimab
Drug: anlotinib
First Posted Date
2024-03-25
Last Posted Date
2024-03-25
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT06327698

Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma

First Posted Date
2024-03-20
Last Posted Date
2024-03-20
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
50
Registration Number
NCT06321939
Locations
🇨🇳

Hunan cancer Hospital, Changsha, Hunan, China

Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.

First Posted Date
2023-09-13
Last Posted Date
2023-09-13
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
300
Registration Number
NCT06033287

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

First Posted Date
2023-09-11
Last Posted Date
2023-09-11
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
106
Registration Number
NCT06031376
Locations
🇨🇳

Hunan Cancer hospital, Changsha, Hunan, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy